A
ATEA PHARMACEUTICALS INC
NASDAQ: AVIR (Atea Pharmaceuticals, Inc.)
Last update: 26 minutes ago4.29
-0.12 (-2.72%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Atea Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | -0.2 |
| AI Technical info | NA |
| Technical Oscillators info | -2.0 |
| Technical Moving Averages info | 2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -17.9% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -1.1 |
| Final Score | -0.08 |
Select this tab to load the latest available analysis.
|
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.79% |
| % Held by Institutions | 66.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bml Capital Management, Llc | 30 Sep 2026 | 6,753,658 |
| Rosalind Advisors, Inc. | 30 Jun 2026 | 1,070,550 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |